Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next

Rapport Therapeutics, Inc. (RAPP) announced an update on their ongoing clinical study.

Rapport Therapeutics (NASDAQ: RAPP) has reported a key update on its Phase 2a study titled “A Phase 2A, Multicenter, Open-label Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy.” The study aims to see whether RAP-219 can reduce seizures and is safe in adults whose focal epilepsy does not respond well to current drugs. This is important because this group has few effective options, and any positive signal could support a new, targeted epilepsy treatment and strengthen Rapport’s clinical story for investors.

The trial tests RAP-219, an oral tablet developed by Rapport Therapeutics. It is given once daily to adults with hard-to-treat focal onset seizures. The goal is to see whether this drug can safely cut seizure frequency and improve control where standard anti-seizure medicines fall short.

The study uses a simple, single-arm design, meaning all participants receive RAP-219 and there is no placebo or comparison drug group. It is open-label, so both doctors and patients know they are taking RAP-219. The main purpose is treatment-focused: to understand safety and early signs of benefit in real-world-like patients before larger, controlled trials.

Participants first receive 0.75 mg of RAP-219 once daily for five days, then increase to 1.25 mg once daily for the rest of an eight-week treatment period. This stepped dosing is meant to help doctors watch for side effects at a lower starting dose, then move to a dose that could offer better seizure control.

The study has an overall status of “Completed,” meaning treatment and follow-up have finished, even though results are not yet posted. The study was first submitted on April 17, 2024, marking the formal start of public tracking. The last update was submitted on February 4, 2026, signaling recent activity on the record and suggesting that data review or preparation for disclosure is underway. Primary and final completion dates are not listed in the extract but, given the status, key data should now exist and may be shared in upcoming company communications or filings.

For investors, the completion of this Phase 2a trial is a key milestone. It reduces some development risk for RAP-219 by signaling that the study ran to conclusion and likely generated evaluable data. Near-term stock performance for RAPP will hinge on how the top-line results compare with market expectations for seizure reduction and safety. Positive signals could boost sentiment, support follow-on trials, and strengthen Rapport’s position in the competitive epilepsy space, where incumbents like UCB (Briviact), SK Biopharmaceuticals (Xcopri) and other CNS-focused players are active. Conversely, any safety issues or weak efficacy could pressure the stock and raise questions around the broader platform. Until data are released, investors may treat this update as a neutral-to-cautious positive, watching closely for the first detailed readout.

The study record for RAP-219 in refractory focal epilepsy is now completed and recently updated, with further details available on the ClinicalTrials.gov portal.

To learn more about RAPP’s potential, visit the Rapport Therapeutics, Inc. drug pipeline page.